{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Embryonal+Neoplasm&page=41",
    "query": {
      "condition": "Embryonal Neoplasm",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 5162,
    "total_pages": 517,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Embryonal+Neoplasm&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Embryonal+Neoplasm&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T08:18:07.631Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01174238",
      "title": "A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adil Daud",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2010-07",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01174238"
    },
    {
      "nct_id": "NCT01552434",
      "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Castleman Disease",
        "Digestive System Carcinoma",
        "Erdheim-Chester Disease",
        "Lip and Oral Cavity Carcinoma",
        "Lymphangioleiomyomatosis",
        "Malignant Endocrine Neoplasm",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Male Reproductive System Neoplasm",
        "Malignant Neoplasm",
        "Malignant Respiratory Tract Neoplasm",
        "Malignant Thoracic Neoplasm",
        "Malignant Urinary System Neoplasm",
        "Mesothelial Neoplasm",
        "Metastatic Malignant Neoplasm",
        "Metastatic Urothelial Carcinoma",
        "Neurofibromatosis Type 2",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Digestive System Carcinoma",
        "Recurrent Female Reproductive System Carcinoma",
        "Recurrent Male Reproductive System Carcinoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Pharyngeal Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Malignant Neoplasm",
        "Soft Tissue Neoplasm",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Pharyngeal Cancer",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Pharyngeal Cancer",
        "Stage IVA Pharyngeal Cancer",
        "Stage IVB Pharyngeal Cancer",
        "Stage IVC Pharyngeal Cancer",
        "Thyroid Gland Neoplasm"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 154,
      "start_date": "2012-10-16",
      "completion_date": "2026-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552434"
    },
    {
      "nct_id": "NCT00582647",
      "title": "Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Esophageal Cancer",
        "Bile Duct Neoplasms",
        "Gastric Cancer",
        "Liver Cancer",
        "Melanoma",
        "Pancreatic Cancer",
        "Sarcoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6000,
      "start_date": "2000-03",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582647"
    },
    {
      "nct_id": "NCT01358058",
      "title": "Proton Radiation Therapy for Gliomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Low Grade Glioma",
        "WHO Grade 3 Glioma With IDH1 Mutation",
        "WHO Grade 3 Glioma With 1p/19q Codeletion"
      ],
      "interventions": [
        {
          "name": "Proton radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2011-05",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01358058"
    },
    {
      "nct_id": "NCT01288235",
      "title": "Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumor",
        "Low Grade Glioma",
        "Astrocytoma",
        "Ependymoma",
        "Ganglioglioma"
      ],
      "interventions": [
        {
          "name": "Proton radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 100,
      "start_date": "2011-02",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01288235"
    },
    {
      "nct_id": "NCT05524935",
      "title": "Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uveal Melanoma",
        "Ocular Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-10-11",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05524935"
    },
    {
      "nct_id": "NCT00274755",
      "title": "Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "magnetic resonance spectroscopic imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2003-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-05-20",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274755"
    },
    {
      "nct_id": "NCT02250885",
      "title": "KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Neuroendocrine"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gabrail Cancer Center Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2014-08",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 1,
      "location_summary": "Canton, Ohio",
      "locations": [
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02250885"
    },
    {
      "nct_id": "NCT02943733",
      "title": "Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Neoplasms",
        "Cancer",
        "Tumors"
      ],
      "interventions": [
        {
          "name": "TAS-102",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2017-08-22",
      "completion_date": "2022-01-31",
      "has_results": false,
      "last_update_posted_date": "2022-09-23",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02943733"
    },
    {
      "nct_id": "NCT01492673",
      "title": "Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide, Topotecan, and Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 9,
      "start_date": "2011-12",
      "completion_date": "2018-10-31",
      "has_results": true,
      "last_update_posted_date": "2019-10-29",
      "last_synced_at": "2026-10-27T08:18:07.631Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Denver, Colorado • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492673"
    }
  ]
}